Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 165-178

  Collet, Guillaume ^a,b   Lamerant Fayel, Nathalie ^a   Tertil, Magdalena ^a,b   El Hafny Rahbi, Bouchra ^a   Stepniewski, Jacek ^b   Guichard, Alan ^a   Foucault Collet, Alexandra ^a   Klimkiewicz, Krzysztof ^a,b   Petoud, Stéphane ^a   Matejuk, Agata ^a,c   Grillon, Catherine ^a   Jozkowicz, Alicja ^b   Dulak, Jozef ^b,c   Kieda, Claudine ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c PLATOV SOUTH RUSSIAN STATE POLYTECHNIC UNIVERSITY NPI   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PARVOVIRUS VECTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL HYPOXIA; CELL STRAIN HEK293; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG RECEPTOR BINDING; EMBRYO; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; STABLE TRANSFECTION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CELL HYPOXIA; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84892600622     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0637     Document Type: Article

References (56)

1. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304-8.
2. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
4. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
6. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
7. Duncan WC, van den Driesche S, Fraser HM. Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxiainducible factor-1alpha in the follicle and corpus luteum. Endocrinology 2008;149:3313-20.
8. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
9. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111.
10. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010;18:171-84.
11. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
12. Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004;5:405-6.
13. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
14. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
15. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008; 7:3670-84.
16. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9: 685-93.
17. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
18. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9: 653-60.
19. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136:839-51.
20. Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 2012;18:161-9.
21. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004;19:176-82.
22. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-90.
23. Dougherty GJ, Dougherty ST. Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Ther 2009;16:279-90.
24. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 2003;31:20-4.
25. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437:169-83.
26. Taipale J, Makinen T, Arighi E, Kukk E, Karkkainen M, Alitalo K. Vascular endothelial growth factor receptor-3. Curr Top Microbiol Immunol 1999;237:85-96.
27. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549-60.
28. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004;2:315-26.
29. Golda S, Kucharzewska P, Cisowski J, Florczyk U, Zagórska A, Jazwa A, et al. Regulation of gene expression in plasmid vectors: doxocyclindependent and hypoxia-regulated systems. Biotechnologia 2007; 3:82-97.
30. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000;60:2936-41.
31. Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA, et al. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 2009;324:804-7.
32. Bizouarne N, Denis V, Legrand A, Monsigny M, Kieda C. A SV-40 immortalized murine endothelial cell line from peripheral lymph node high endothelium expresses a new alpha-L-fucose binding protein. Biol Cell 1993;79:209-18.
33. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992;99:683-90.
34. Jazwa A, Stepniewski J, Zamykal M, Jagodzinska J, Meloni M, Emanueli C, et al. Pre-emptive hypoxia-regulated HO-1 gene therapy improves post-ischaemic limb perfusion and tissue regeneration in mice. Cardiovasc Res 2013;97:115-24.
35. Carreau A, Kieda C, Grillon C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp Cell Res 2011;317:29-41.
36. Cheng T, Xu CY, Wang YB, Chen M, Wu T, Zhang J, et al. A rapid and efficient method to express target genes in mammalian cells by baculovirus. World J Gastroenterol 2004;10:1612-8.
37. Davis MG, Huang ES. Transfer and expression of plasmids containing human cytomegalovirus immediate-early gene 1 promoter-enhancer sequences in eukaryotic and prokaryotic cells. Biotechnol Appl Biochem 1988;10:6-12.
38. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
39. 2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl) 2013;91:883-99.
40. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008;68:521-9.
41. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011;15:1239-53.
42. Collet G, Skrzypek K, Grillon C, Matejuk A, El Hafni-Rahbi B, Lamerant-Fayel N, et al. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascul Pharmacol 2012;56:252-61.
43. Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, et al. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEB J 2010;24:3782-95.
44. Kieda C, Greferath R, Crola da Silva C, Fylaktakidou KC, Lehn JM, Nicolau C. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci U S A 2006;103:15576-81.
45. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 2008;15:877-84.
46. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009;16:473-88.
47. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-99.
48. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, Aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14.
49. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
50. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
51. van der Bilta AR, van der Zee AG, de Vries EG, de Jong S, Timmer-Bosscha H, Ten Hoor KA, et al. Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. Curr Pharm Des 2012;18:3784-92.
52. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013;19:1557-66.
53. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One 2012;7:e38231.
54. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, et al. Safety, efficacy, and biomarker exploration in a phase ii study of bevacizumab, oxaliplatin, and gemcitabine in recurrent mullerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig 2011;4:26-33.
55. Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Ruegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010;30:529-45.
56. Paprocka M, Krawczenko A, Dus D, Kantor A, Carreau A, Grillon C, et al. CD133 positive progenitor endothelial cell lines from human cord blood. Cytometry A 2011;79:594-602.